Laura Hurley
Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 45 | 2026 | 1428 | 4.030 |
Why?
| | Physicians, Primary Care | 16 | 2024 | 208 | 3.840 |
Why?
| | Practice Patterns, Physicians' | 25 | 2024 | 1372 | 2.300 |
Why?
| | Attitude of Health Personnel | 28 | 2024 | 1196 | 2.210 |
Why?
| | Influenza Vaccines | 16 | 2025 | 534 | 2.090 |
Why?
| | Vaccines | 14 | 2025 | 389 | 2.040 |
Why?
| | Pneumococcal Vaccines | 7 | 2025 | 129 | 2.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 13 | 2025 | 1419 | 1.970 |
Why?
| | Herpes Zoster Vaccine | 7 | 2022 | 154 | 1.850 |
Why?
| | Physicians, Family | 11 | 2021 | 177 | 1.500 |
Why?
| | Vaccination Coverage | 4 | 2026 | 102 | 1.470 |
Why?
| | Influenza, Human | 11 | 2023 | 624 | 1.340 |
Why?
| | Herpes Zoster | 4 | 2022 | 319 | 1.310 |
Why?
| | Health Care Surveys | 13 | 2021 | 536 | 1.180 |
Why?
| | Immunization | 8 | 2021 | 375 | 1.080 |
Why?
| | Self Report | 6 | 2026 | 875 | 1.060 |
Why?
| | Papillomavirus Vaccines | 8 | 2021 | 296 | 0.970 |
Why?
| | Surveys and Questionnaires | 24 | 2025 | 6084 | 0.940 |
Why?
| | Immunization Schedule | 9 | 2021 | 186 | 0.870 |
Why?
| | Immunization, Secondary | 1 | 2025 | 92 | 0.860 |
Why?
| | Primary Health Care | 10 | 2024 | 1736 | 0.820 |
Why?
| | Physicians | 10 | 2022 | 956 | 0.820 |
Why?
| | Papillomavirus Infections | 5 | 2021 | 344 | 0.810 |
Why?
| | Vaccines, Synthetic | 3 | 2026 | 137 | 0.780 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2025 | 39 | 0.770 |
Why?
| | Guideline Adherence | 4 | 2024 | 587 | 0.760 |
Why?
| | Asthma | 6 | 2025 | 1797 | 0.740 |
Why?
| | Pediatricians | 7 | 2022 | 121 | 0.720 |
Why?
| | Adult | 49 | 2026 | 40867 | 0.710 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 544 | 0.710 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 4 | 2019 | 91 | 0.710 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 139 | 0.710 |
Why?
| | General Practitioners | 2 | 2021 | 26 | 0.680 |
Why?
| | Internal Medicine | 5 | 2014 | 279 | 0.670 |
Why?
| | Reminder Systems | 3 | 2018 | 140 | 0.650 |
Why?
| | Insurance, Health, Reimbursement | 4 | 2018 | 98 | 0.640 |
Why?
| | Middle Aged | 43 | 2026 | 36297 | 0.640 |
Why?
| | Vaccination Refusal | 5 | 2021 | 61 | 0.630 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2016 | 103 | 0.580 |
Why?
| | Family Practice | 10 | 2017 | 407 | 0.550 |
Why?
| | United States | 37 | 2026 | 16122 | 0.540 |
Why?
| | Pneumococcal Infections | 2 | 2018 | 104 | 0.520 |
Why?
| | Humans | 83 | 2026 | 145750 | 0.520 |
Why?
| | Immunization Programs | 6 | 2020 | 193 | 0.520 |
Why?
| | Female | 53 | 2026 | 79025 | 0.490 |
Why?
| | Practice Guidelines as Topic | 8 | 2024 | 1582 | 0.490 |
Why?
| | Male | 47 | 2026 | 72992 | 0.460 |
Why?
| | Clinical Competence | 3 | 2018 | 1247 | 0.440 |
Why?
| | Aged | 20 | 2026 | 26212 | 0.430 |
Why?
| | Preventive Health Services | 1 | 2016 | 153 | 0.410 |
Why?
| | Data Mining | 2 | 2025 | 113 | 0.410 |
Why?
| | Pediatrics | 11 | 2021 | 1124 | 0.390 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1101 | 0.390 |
Why?
| | Insurance, Health | 1 | 2016 | 311 | 0.380 |
Why?
| | Hepatitis A | 2 | 2026 | 25 | 0.360 |
Why?
| | Meningococcal Vaccines | 3 | 2018 | 57 | 0.350 |
Why?
| | Mumps | 2 | 2022 | 21 | 0.350 |
Why?
| | Anti-Asthmatic Agents | 2 | 2025 | 260 | 0.330 |
Why?
| | Health Services Research | 2 | 2018 | 391 | 0.320 |
Why?
| | Medicare Part D | 1 | 2010 | 23 | 0.310 |
Why?
| | Age Factors | 8 | 2021 | 3346 | 0.310 |
Why?
| | Hepatitis B Vaccines | 2 | 2026 | 43 | 0.300 |
Why?
| | Hepatitis B | 2 | 2026 | 66 | 0.300 |
Why?
| | Electronic Health Records | 4 | 2026 | 1202 | 0.290 |
Why?
| | Young Adult | 10 | 2026 | 14250 | 0.290 |
Why?
| | Rotavirus Vaccines | 3 | 2021 | 39 | 0.290 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 364 | 0.280 |
Why?
| | Nephrology | 1 | 2009 | 60 | 0.280 |
Why?
| | Neuralgia, Postherpetic | 1 | 2008 | 40 | 0.270 |
Why?
| | Rotavirus Infections | 2 | 2021 | 37 | 0.260 |
Why?
| | Minority Groups | 1 | 2010 | 285 | 0.260 |
Why?
| | Gynecology | 3 | 2019 | 181 | 0.260 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2025 | 81 | 0.260 |
Why?
| | Colorado | 6 | 2026 | 4556 | 0.250 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5921 | 0.250 |
Why?
| | Adrenal Cortex Hormones | 3 | 2025 | 484 | 0.240 |
Why?
| | Hepatitis A Vaccines | 1 | 2026 | 19 | 0.240 |
Why?
| | Safety-net Providers | 2 | 2025 | 130 | 0.240 |
Why?
| | Emigrants and Immigrants | 1 | 2009 | 158 | 0.240 |
Why?
| | Meningococcal Infections | 2 | 2018 | 26 | 0.220 |
Why?
| | Medicaid | 3 | 2025 | 467 | 0.220 |
Why?
| | Vaccines, Conjugate | 2 | 2018 | 59 | 0.220 |
Why?
| | Adolescent | 14 | 2026 | 22569 | 0.220 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 440 | 0.210 |
Why?
| | Professional-Family Relations | 2 | 2016 | 153 | 0.200 |
Why?
| | Health Expenditures | 1 | 2025 | 194 | 0.200 |
Why?
| | Physician-Patient Relations | 3 | 2019 | 588 | 0.200 |
Why?
| | Tinnitus | 1 | 2024 | 69 | 0.190 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 599 | 0.190 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2025 | 81 | 0.190 |
Why?
| | Beclomethasone | 1 | 2022 | 8 | 0.180 |
Why?
| | Pregnancy | 7 | 2026 | 7215 | 0.180 |
Why?
| | Child | 16 | 2026 | 22738 | 0.180 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2022 | 57 | 0.180 |
Why?
| | Rubella | 1 | 2022 | 23 | 0.180 |
Why?
| | Neisseria meningitidis, Serogroup B | 2 | 2018 | 15 | 0.180 |
Why?
| | Measles | 1 | 2022 | 46 | 0.170 |
Why?
| | Herpesvirus 3, Human | 2 | 2019 | 343 | 0.170 |
Why?
| | Refusal to Treat | 1 | 2020 | 16 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 660 | 0.160 |
Why?
| | Standing Orders | 1 | 2020 | 10 | 0.160 |
Why?
| | Insurance Coverage | 3 | 2018 | 244 | 0.160 |
Why?
| | Norovirus | 1 | 2020 | 22 | 0.150 |
Why?
| | Advisory Committees | 1 | 2021 | 229 | 0.150 |
Why?
| | Policy | 1 | 2020 | 149 | 0.150 |
Why?
| | Gastroenteritis | 1 | 2020 | 63 | 0.150 |
Why?
| | Obstetrics | 2 | 2019 | 177 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2020 | 740 | 0.140 |
Why?
| | Cost of Illness | 2 | 2018 | 324 | 0.140 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2020 | 159 | 0.140 |
Why?
| | Administration, Inhalation | 3 | 2025 | 571 | 0.130 |
Why?
| | Professional Practice | 1 | 2018 | 57 | 0.130 |
Why?
| | Awareness | 1 | 2018 | 110 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2022 | 532 | 0.130 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2190 | 0.130 |
Why?
| | Patients | 1 | 2018 | 183 | 0.120 |
Why?
| | Health Plan Implementation | 1 | 2018 | 141 | 0.120 |
Why?
| | Infant | 8 | 2026 | 10089 | 0.120 |
Why?
| | Information Systems | 1 | 2016 | 56 | 0.120 |
Why?
| | Physician's Role | 2 | 2019 | 225 | 0.120 |
Why?
| | Quality of Life | 3 | 2023 | 3210 | 0.120 |
Why?
| | Directive Counseling | 1 | 2016 | 45 | 0.120 |
Why?
| | Text Messaging | 1 | 2018 | 182 | 0.110 |
Why?
| | Parents | 4 | 2021 | 1404 | 0.110 |
Why?
| | Self-Management | 1 | 2018 | 202 | 0.110 |
Why?
| | Treatment Refusal | 1 | 2015 | 99 | 0.110 |
Why?
| | Attitude to Health | 1 | 2017 | 430 | 0.100 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 528 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 3 | 2016 | 883 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 425 | 0.100 |
Why?
| | Medicare | 2 | 2018 | 904 | 0.100 |
Why?
| | Documentation | 1 | 2015 | 199 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2017 | 409 | 0.100 |
Why?
| | Health Surveys | 2 | 2018 | 520 | 0.100 |
Why?
| | Medically Uninsured | 1 | 2014 | 132 | 0.100 |
Why?
| | Tumor Microenvironment | 1 | 2017 | 735 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 201 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8346 | 0.090 |
Why?
| | Neisseria meningitidis | 1 | 2011 | 23 | 0.090 |
Why?
| | Fibroblasts | 1 | 2017 | 1027 | 0.090 |
Why?
| | Safety | 1 | 2013 | 358 | 0.080 |
Why?
| | Fees, Pharmaceutical | 1 | 2010 | 8 | 0.080 |
Why?
| | Product Surveillance, Postmarketing | 2 | 2025 | 74 | 0.080 |
Why?
| | Internet | 2 | 2019 | 693 | 0.070 |
Why?
| | Data Collection | 4 | 2014 | 643 | 0.070 |
Why?
| | Mexican Americans | 1 | 2010 | 119 | 0.070 |
Why?
| | ROC Curve | 1 | 2010 | 618 | 0.070 |
Why?
| | Regression Analysis | 2 | 2020 | 1001 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2014 | 868 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 971 | 0.060 |
Why?
| | Electronic Mail | 2 | 2018 | 60 | 0.060 |
Why?
| | Costs and Cost Analysis | 2 | 2018 | 221 | 0.060 |
Why?
| | Health Personnel | 3 | 2019 | 755 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1330 | 0.060 |
Why?
| | Child, Preschool | 4 | 2026 | 11866 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 426 | 0.060 |
Why?
| | Hospitalization | 2 | 2026 | 2460 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 466 | 0.050 |
Why?
| | Risk Assessment | 2 | 2015 | 3752 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2123 | 0.050 |
Why?
| | Seasons | 2 | 2020 | 538 | 0.050 |
Why?
| | Vaccines, Combined | 1 | 2023 | 49 | 0.050 |
Why?
| | Nebulizers and Vaporizers | 1 | 2023 | 62 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 2023 | 63 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2024 | 421 | 0.050 |
Why?
| | Symptom Flare Up | 1 | 2022 | 37 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2022 | 48 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2009 | 947 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7133 | 0.040 |
Why?
| | Mumps Vaccine | 1 | 2021 | 11 | 0.040 |
Why?
| | Incidence | 2 | 2024 | 2933 | 0.040 |
Why?
| | Kidney | 1 | 2009 | 1498 | 0.040 |
Why?
| | Risk Factors | 3 | 2010 | 10916 | 0.040 |
Why?
| | Hypertension | 1 | 2009 | 1276 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2021 | 70 | 0.040 |
Why?
| | Vaccines, Attenuated | 1 | 2021 | 129 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2020 | 133 | 0.040 |
Why?
| | Qualitative Research | 2 | 2018 | 1676 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.040 |
Why?
| | Cohort Studies | 2 | 2025 | 6032 | 0.040 |
Why?
| | Pandemics | 2 | 2021 | 1711 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2022 | 419 | 0.040 |
Why?
| | Postal Service | 1 | 2018 | 27 | 0.040 |
Why?
| | Serogroup | 1 | 2018 | 45 | 0.030 |
Why?
| | Diphtheria | 1 | 2017 | 21 | 0.030 |
Why?
| | Tetanus | 1 | 2017 | 26 | 0.030 |
Why?
| | Pharmacists | 1 | 2021 | 258 | 0.030 |
Why?
| | Population Groups | 1 | 2017 | 56 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.030 |
Why?
| | Whooping Cough | 1 | 2017 | 55 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1547 | 0.030 |
Why?
| | Professional Practice Gaps | 1 | 2016 | 15 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 37 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 680 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2023 | 2805 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 570 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1261 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 273 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1751 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 2110 | 0.020 |
Why?
| | Circovirus | 1 | 2013 | 5 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2021 | 2967 | 0.020 |
Why?
| | Intussusception | 1 | 2013 | 26 | 0.020 |
Why?
| | Life Style | 1 | 2015 | 486 | 0.020 |
Why?
| | Communication | 1 | 2019 | 976 | 0.020 |
Why?
| | Drug Contamination | 1 | 2013 | 54 | 0.020 |
Why?
| | Societies, Medical | 1 | 2017 | 900 | 0.020 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 273 | 0.020 |
Why?
| | Professional Practice Location | 1 | 2011 | 26 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2026 | 17322 | 0.020 |
Why?
| | Community-Institutional Relations | 1 | 2012 | 100 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1101 | 0.020 |
Why?
| | Swine | 1 | 2013 | 826 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11793 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4151 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2017 | 2051 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 6464 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 3551 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5428 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2009 | 225 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 252 | 0.020 |
Why?
| | Risk-Taking | 1 | 2009 | 323 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 765 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 2139 | 0.010 |
Why?
| | Chronic Disease | 1 | 2009 | 1810 | 0.010 |
Why?
| | Animals | 2 | 2017 | 38100 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18357 | 0.010 |
Why?
|
|
Hurley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|